Unpublished research (courtesy of GeneMarkers, USA) shows that CBD, in the concentration and delivery vehicle of our CBD Serum, activates more than 165 genes in the skin. The total number of genes affected was 537 (481 up-regulated and 56 down-regulated). Approximately 39% of the main genes involved directly impact skin barrier formation, integrity and hydration – the reduction of trans-epidermal water loss, stimulation of filaggrin and NMF production. Next most important was the down-regulation of inflammation and allergic responses and thirdly, the promotion of wound healing and stimulation of growth factors. Other significant genes activated relate to acne and hyperpigmentation.
CBD up-regulates IL-37 (Interleukin 37), a cytokine. IL‑37 plays a vital role in inhibiting both innate and adaptive immune responses as well as inflammatory reactions. In addition, IL‑37 may prove to be a new and potentially useful target for effective cytokine therapy in auto-immune diseases and some cancers. In the skin, IL-37 dramatically blocks IL-6 and other inflammatory cytokines secreted by macrophages, yet promotes the production of IL-10 (also an anti-inflammatory cytokine) and modulates the immune response. This has potential ramifications in the treatment of conditions like psoriasis, eczema, dermatitis etc.
These results demonstrate that CBD has the potential to become as important as all-trans retinoids in skin care and skin health. In fact, the two are extremely compatible. As results are further analysed, no doubt other new and exciting markers will emerge. And best of all, this work is all being done in vitro, with no animal testing.